G Meloni

795 citations
24 papers · 547 indexed · h-index 11

G Meloni

24 papers receiving 522 citations

Peers

G Meloni
Comparison fields: 5 of 53
  • Hematology 461
  • Genetics 268
  • Rheumatology 118
  • Public Health, Environmental and Occupational Health 99
  • Pathology and Forensic Medicine 57
Replace William A. Wyatt with:
William A. Wyatt United States
SL George United States
Enrica Lerma Italy
D. C. van der Plas Netherlands
Rokuo Abe Japan
Teresa Davies United Kingdom
Michela Rondoni Italy
B Clarkson United States
Dominique Mühlematter Switzerland
RT Silver United States
G Meloni relative to William A. Wyatt United States William A. Wyatt's profile →
Citations per field
00.5×
William A. Wyatt · 1×
Citations per year

Countries citing papers authored by G Meloni

Since Specialization
Citations

This map shows the geographic impact of G Meloni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Meloni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Meloni more than expected).

Fields of papers citing papers by G Meloni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Meloni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Meloni. The network helps show where G Meloni may publish in the future.

Co-authorship network

The 25 scholars most cited alongside G Meloni, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with G Meloni Line = papers co-authored together G Meloni links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1
Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris.
201438
2
A SEQUENTIAL USE OF TKI, CHEMOTHERAPY AND TRANSPLANT IS ASSOCIATED WITH HIGH COMPLETE REMISSION RATES, DISEASE-FREE AND OVERALL SURVIVAL IN ADULT PH+ ALL. RESULTS OF THE GIMEMA 0904 PROTOCOL
20131
3 200320
4
Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease.
20023
5
Autologous transplantation with peripheral blood stem cells in chronic lymphocytic leukemia
19992
6 199930
7
Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
199930
8
Autologous peripheral blood stem cell transplantation in a patient with multiple sclerosis and concomitant Ph+ acute leukemia.
199915
9 1996257
10 19953
11
Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia in remission: first choice for isolated extramedullary relapse?
19949
12
Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Chronic Leukemia Working Party of the EBMT.
199445
13
Autologous transplantation in chronic myelogenous leukemia: European results: Chronic Leukemia Working Party of the EBMT.
19945
14
Allogeneic vs autologous BMT vs intensive chemotherapy in childhood AnLL during first complete remission: AIEOP experience. AIEOP Cooperative Group.
19912
15
Idarubicin plus ARA-C followed by allogeneic or autologous bone marrow transplantation in advanced acute lymphoblastic leukemia.
199112
16
Evaluation of late side-effects after bone marrow transplantation in children with leukemia.
19919
17
Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion.
199012
18
Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission.
19896
19
Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission.
198923
20
High-dose chemotherapy and autologous stem cell infusion in patients with chronic myelogenous leukaemia in early phase of the disease
19883

About G Meloni

G Meloni is a scholar working on Hematology, Genetics and Biochemistry, having authored 24 papers that have together received 547 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (10 papers), Acute Myeloid Leukemia Research (7 papers), Hematopoietic Stem Cell Transplantation (7 papers), Chronic Lymphocytic Leukemia Research (4 papers), Acute Lymphoblastic Leukemia research (3 papers), Multiple Myeloma Research and Treatments (2 papers), Lymphoma Diagnosis and Treatment (2 papers) and Testicular diseases and treatments (1 paper). The work is most often cited by research in Hematology (461 citations), Genetics (268 citations) and Rheumatology (118 citations). G Meloni has collaborated with scholars based in Italy, France and United Kingdom. Frequent co-authors include Giuseppe Saglio, Fabrizio Pane, Bruno Rotoli, F. Ferrara, Francesco Salvatore, Ferdinando Frigeri, Luigia Luciano, Franco Mandelli, Josy Reiffers and J M Goldman. Their work appears in journals such as Blood, Bone Marrow Transplantation, British Journal of Haematology, Acta Haematologica and Leukemia Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026